The Era of Rebate Rip-offs Is Over (Maybe)
News
- Mar 1
Drug-Prices Investigation Focused on Middlemen Opens in Congress
- Feb 28
Video: Senators Criticize PBMs at Recent Hearing
- Feb 17
PBMs Get Heavy Dose of Criticism at Senate Hearing
- Feb 17
Senate Committee Puts PBMs Under the Microscope
- Feb 17
Senate begins quest to demystify PBMs' practices as it mulls legislation
- Feb 17
'In the crosshairs': PBM reform effort intensifies on Capitol Hill
- Feb 16
Chairman of the Board Response to U.S. Senators’ Efforts to Hold PBMs Accountable
- Feb 16
Senators question why PBMs 'even exist' in heated hearing amid push for reform
- Feb 16
Tough day for PBMs
- Feb 15
How 3 companies came to dominate the PBM market
- Feb 14
Mark Cuban Assails PBMs at AAM meeting
- Feb 14
Health care giant Centene settles with another state, California
- Feb 8
PBMA Chairman of the Board Response to State of the Union address
- Feb 8
Biden’s SOTU Targets Drug Companies, But Misses Opportunity To Challenge Health Insurers And PBMs
- Feb 7
Need a new drug? You may be asked to ‘fail’ an old drug first
- Feb 7
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
- Feb 2
Bipartisan Policy Center Brief: High Drug Prices: Are PBMs the Right Target?
- Feb 1
Centene to pay $66.5 million in Indiana Medicaid drug pricing settlement
- Jan 21
Corporate bad actors make billions from abusing program designed to help low-income patients | Guest
- Jan 20
Why Now Is the Time for Health Plans to Take Control of Pharmacy Benefits
- Jan 15
It is Time for Policymakers to Protect Patients from Predatory Practices of Insurers and PBMs
- Jan 14
Lawmakers are readying fresh attacks on pharmacy middlemen
- Jan 13
With the FTC’s more expansive approach to antitrust, PBMs are in the crosshairs